•
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced that its IL-4Rα monoclonal antibody (mAb) drug candidate, CM310, has successfully reached its primary endpoints in a confirmatory Phase III clinical study for the treatment of moderate to severe atopic dermatitis (AD). Phase III Study…
•
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based in China, has joined forces with Venus Medtech (Hangzhou) Inc., another prominent player in the medical field (HKG: 2500), to announce the establishment of a partnership fund. Each company is contributing RMB 125 million (USD…
•
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the UK-based pharmaceutical giant is planning to triple its investment in research and development in China over the coming months. This strategic move aims to increase the number of innovative drugs entering the Chinese market, as…
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the fourth quarter of 2022. The company reported Q4 revenues of CNY 142.2 million (USD 20.6 million), marking a 3.5% decrease year-on-year (YOY). However, for the full 12 months, revenues showed a positive trend, increasing by…
•
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius Bio’s HLX208, and LianBio’s infigratinib are all set to be awarded priority review status as Category 1 chemical drugs. TQB3454: A Promising IDH1 Mutase InhibitorTQB3454 is an in-house developed IDH1 mutase inhibitor intended for the…
•
Brii Biosciences has announced a strategic decision to end the manufacturing and further development of the amubarvimab/romlusevimab combination treatment regimen for COVID-19. According to the company’s recent 2022 financial report, the antibody cocktail had been commercially available in China from July 2022 following an emergency use authorization (EUA) and had…
•
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary of BGI Group (SHE: 300676), based in China. The collaboration aims to localize and transform comprehensive cancer care by introducing automation platforms for sequencing pipelines across the entire cycle of precise diagnosis and treatment of…
•
PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a new R&D facility in West Chester, Pennsylvania. This strategic move aims to expand the company’s presence in the United States and offer more efficient process R&D services, enabling the fast delivery of clinical-stage GMP projects…
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s Otezla (apremilast) has obtained marketing approval from the National Medical Products Administration (NMPA), signifying that it has passed the generic quality and efficacy consistency evaluation. Apremilast’s Background and Clinical Necessity in ChinaApremilast, an oral small…
•
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK). This strategic partnership will see the combination of BJ Bio’s pipeline candidate, BJ-001, with MSD’s programmed death-1 (PD-1) inhibitor, Keytruda (pembrolizumab), in a Phase I clinical trial…
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval for its Vericor peripheral support catheter from the Thailand Food and Drug Administration. This development marks a significant step for the company as it expands the reach of its medical devices in the Southeast Asian…
•
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a Phase II trial for its pipeline candidate CAN008 (asunercept) in combination with temozolomide for the treatment of glioblastoma multiforme (GBM). The multi-center, randomized, placebo-controlled study, which is potentially registrational, has recruited a total of 117…
•
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing for its in-house developed Category 1 biological product, Xeligekimab, for the treatment of moderate to severe plaque psoriasis has been accepted for review. This development marks a significant step forward for the company and the…
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022. As of December 31, 2022, the company reported revenues of RMB 9.382 billion (USD 1.362 billion), a decrease of 5.6% year-on-year (YOY). Despite this, the sales revenue of innovative drugs reached RMB 5.006 billion (USD…
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for 2022, highlighting revenues of RMB 43.952 billion (USD 6.381 billion), marking a 12.66% increase year-on-year (YOY). The company’s net profits also saw a significant rise, reaching RMB 3.873 billion (USD 562.4 million), up 18.17%…
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency Use Authorization (EUA) for its in-house developed COVID-19 mRNA vaccine, SYS6006, in China. This approval marks a significant milestone as it is the first for a domestically developed mRNA product in the country. Design and…
•
US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of its Athletis peripheral balloon dilatation catheter in mainland China. The product is designed for percutaneous transluminal angioplasty (PTA) of the peripheral vascular system and is utilized in the treatment of stenotic lesions in autologous or…
•
China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private placement of 355 million shares, aiming to collect RMB 1.34 billion (USD 194.8 million). The funds procured will be allocated towards several key projects, including the expansion of peritoneal dialysate production capacity, the construction of…
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a distribution and supply agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd for NVK002, an atropine external use eye solution. Under the terms of the agreement, Kwangdong will assume import, publicity, distribution, marketing, and sales…
•
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has obtained clinical trial approvals for two in-house developed drugs: CD80 mutant Fc fusion protein XZP-KM602 and DNA dependent protein kinase (DNA-PK) inhibitor XZP-6877. Both drugs are aimed at treating advanced solid…